Employees: 808
Size MiMedx (MDXG) is a United States Health Care company (Medical Specialties) with a market value of $464M, the 2732nd largest of 3,085 United States companies the cockpit tracks. Shares closed at $3.18 on 18 Nov 2026.
Performance Over six months the shares fell 16.1%, against -14.2% for the median peer and -2.2% for the United States market (cap-weighted) — 10th lowest of 21 in its peer set.
Growth Revenue fell 22.8% over the last twelve months (peer median +3.9%); the operating margin is -8.3% (peer median 6.1%).
Valuation It trades at 1.1× enterprise value to sales against a peer median of 3.6× (cheapest of 19).
Price implies For today's price to make sense, revenue must grow about 11% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is -0 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 32.9 points below its cost of capital (10.9% WACC).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $304M | $419M | $349M | $321M | $268M |
| Revenue growth | — | +20% | +9% | +20% | — |
| Gross profit | $234M | $344M | $287M | $265M | $217M |
| EBITDA | -$17.3M | $78.8M | $62.4M | $40.5M | -$10.7M |
| Net income | -$19.2M | $48.6M | $42.4M | $58.2M | -$30.2M |
| Free cash flow | $19.0M | $73.0M | $64.5M | $24.8M | -$19.4M |
| Capital expenditure | $3.81M | $3.12M | $1.72M | $2.15M | $2.68M |
| Total debt | $0 | $22.5M | $24.8M | $50.5M | $52.5M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MDXG | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -24.8% | -3.4% | lowest of 21 |
| 6-month return | -16.1% | -14.2% | 10th lowest of 21 |
| Distance from 52-week high | -57.3% | -36.1% | lowest of 21 |
| Revenue growth (TTM) | -22.8% | +3.9% | 3rd lowest of 20 |
| Operating margin | -8.3% | 6.1% | 5th lowest of 20 |
| EV / Sales | 1.1× | 3.6× | cheapest of 19 |
| Growth the price implies (Req g, 7 yrs) | 10.9% | 6.5% | 6th most demanding of 13 |
| Growth delivered (Del g) | +11.0% | +1.2% | 2nd highest of 13 |
| Hurdle (Req g minus delivered) | -0.1 pp | +3.7 pp | 6th least demanding of 13 |
| ROIC minus cost of capital | -32.9 pp | -1.6 pp | 2nd lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| MiMedx MDXG | United States | $464M | -16% | -23% | -8% | 1.1× | 10.9% | +11.0% |
| Eiken Chemical 4549.T | Japan | $466M | -20% | +4% | 6% | 1.6× | n/a | n/a |
| Beijing Leadman Biochemistry 300289.SZ | China | $460M | -9% | +46% | 1% | 8.2× | 36.0% | -6.9% |
| PROTEINA 468530.KS | South Korea | $460M | +5% | -59% | -1,178% | 410.3× | n/a | n/a |
| WELL LEAD MEDICAL 603309.SS | China | $473M | -22% | +1% | 15% | 2.0× | -5.9% | +7.7% |
| Guangdong Shirongzhaoye 002016.SZ | China | $453M | -26% | -31% | 3% | 3.8× | 21.5% | -11.7% |
| AngioDynamics ANGO | United States | $476M | -4% | +8% | -6% | 1.4× | n/a | n/a |
| Shanghai Kindly Enterprises Development 603987.SS | China | $452M | -12% | 0% | 10% | 1.5× | -1.0% | -2.8% |
| CellaVision CEVI.ST | Sweden | $477M | +64% | +2% | 23% | 6.1× | 7.1% | +10.0% |
| Guangdong Biolight Meditech 300246.SZ | China | $478M | -35% | +7% | -8% | 3.1× | 55.3% | -4.7% |
| Medprin Regenerative Medical Technologies 301033.SZ | China | $482M | -14% | +23% | 31% | 7.0× | 4.3% | +24.4% |
| Hangzhou Alltest Biotech 688606.SS | China | $484M | -20% | 0% | 13% | 1.3× | -6.5% | -4.3% |
| Wuhan Easy Diagnosis Biomedicine 002932.SZ | China | $485M | -14% | -9% | -51% | n/a | n/a | n/a |
| Clarity Pharmaceuticals CU6.AX | Australia | $444M | -33% | n/a | n/a | n/a | n/a | n/a |
| Huaren Pharmaceutical 300110.SZ | China | $440M | -16% | -3% | 6% | 3.3× | 5.8% | +0.3% |
| Zhejiang Starry Pharmaceutical 603520.SS | China | $491M | -44% | +9% | 3% | 2.2× | n/a | n/a |
| Guangzhou Jet Bio-Filtration 688026.SS | China | $436M | +39% | +5% | 11% | 4.8× | 20.6% | +2.2% |
| medmix MEDX.SW | Switzerland | $494M | +11% | -7% | 6% | 1.4× | 4.5% | +5.0% |
| Mobia Medical MOBI | United States | $434M | +2% | +105% | -145% | 8.8× | n/a | n/a |
| Shoulder Innovations SI | United States | $432M | +39% | +55% | -54% | 5.5× | n/a | n/a |
| Nanjing Vishee Medical Technology 688580.SS | China | $499M | -43% | +7% | 24% | 5.3× | 20.1% | +4.2% |